Transforming Growth Factor-beta: a Clinical Target for the Treatment of Diabetic Nephropathy

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2004 Nov 13

PMID 15539010

Citations 11

Authors

Tracy A McGowan

Yanqing Zhu

Kumar Sharma

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy is continuing to rise in incidence, despite awareness of tight glycemic control and blood pressure. The identification that matrix accumulation is driven by transforming growth factor-beta (TGF-beta) has led to a concerted effort to apply antifibrotic strategies for this disorder. Recent studies have not only demonstrated the beneficial effects of blocking TGF-beta on matrix accumulation but have also found that blocking TGF-beta may have important hemodynamic effects that are relevant to diabetic complications. In this article, we review the latest knowledge regarding the role of TGF-beta in diabetic kidney disease and discuss available and novel therapeutic approaches. The role of a novel antifibrotic drug, pirfenidone, may have important clinical relevance to diabetic nephropathy.

Citing Articles

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

DeFronzo R, Reeves W, Awad A Nat Rev Nephrol. 2021; 17(5):319-334.

PMID: 33547417 DOI: 10.1038/s41581-021-00393-8.

Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.

Zhang H, Nair V, Saha J, Atkins K, Hodgin J, Saunders T Kidney Int. 2017; 92(4):909-921.

PMID: 28554737 PMC: 5610635. DOI: 10.1016/j.kint.2017.03.027.

Diabetes and Kidney Disease: Role of Oxidative Stress.

Jha J, Banal C, Chow B, Cooper M, Jandeleit-Dahm K Antioxid Redox Signal. 2016; 25(12):657-684.

PMID: 26906673 PMC: 5069735. DOI: 10.1089/ars.2016.6664.

Xiaokeping mixture inhibits diabetic nephropathy in streptozotocin-induced rats through blocking TGF-β1/Smad7 signaling.

Xin C, Xia Z, Jiang C, Lin M, Li G Drug Des Devel Ther. 2015; 9:6269-74.

PMID: 26664048 PMC: 4670018. DOI: 10.2147/DDDT.S93964.

Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Wang T, Chen S, Chen R, Yu D, Yu P Int J Clin Exp Med. 2015; 8(5):6852-65.

PMID: 26221223 PMC: 4509168.

References

Border W, Noble N, Yamamoto T, Harper J, Yamaguchi Y, Pierschbacher M . Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992; 360(6402):361-4. DOI: 10.1038/360361a0. View

Dahly A, Hoagland K, Flasch A, Jha S, Ledbetter S, Roman R . Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol. 2002; 283(3):R757-67. DOI: 10.1152/ajpregu.00098.2002. View

Strutz F, Muller G . Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press Res. 1999; 22(1-2):71-80. DOI: 10.1159/000025911. View

Agarwal R, Siva S, Dunn S, Sharma K . Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis. 2002; 39(3):486-92. DOI: 10.1053/ajkd.2002.31392. View

Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S . Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol. 2003; 285(6):F1258-70. DOI: 10.1152/ajprenal.00145.2003. View

Houlihan C, Akdeniz A, Tsalamandris C, Cooper M, Jerums G, Gilbert R . Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care. 2002; 25(6):1072-7. DOI: 10.2337/diacare.25.6.1072. View

Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N . Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol. 1997; 52(1):77-8. DOI: 10.1007/s002280050252. View

Riser B, Cortes P, Heilig C, Grondin J, Patterson D, Narins R . Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol. 1996; 148(6):1915-23. PMC: 1861662. View

Al-Bayati M, Xie Y, Mohr F, Margolin S, Giri S . Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol. 2002; 64(3):517-25. DOI: 10.1016/s0006-2952(02)01213-3. View

10.

Flores L, Vidal M, Abian J, Cases A, Campistol J, Claria J . The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. Diabet Med. 2004; 21(3):285-9. DOI: 10.1111/j.1464-5491.2004.01133.x. View

11.

Ziyadeh F . The extracellular matrix in diabetic nephropathy. Am J Kidney Dis. 1993; 22(5):736-44. DOI: 10.1016/s0272-6386(12)80440-9. View

12.

Sharma K, Jin Y, Guo J, Ziyadeh F . Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45(4):522-30. DOI: 10.2337/diab.45.4.522. View

13.

Yamamoto M, Nakamura H, Yamato M, Aoyagi M, Yamamoto K . Retardation of phenotypic transition of rabbit arterial smooth muscle cells in three-dimensional primary culture. Exp Cell Res. 1996; 225(1):12-21. DOI: 10.1006/excr.1996.0152. View

14.

Giri S, Al-Bayati M, Du X, Schelegle E, Mohr F, Margolin S . Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol. 2003; 53(2):141-50. DOI: 10.1007/s00280-003-0703-z. View

15.

Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K . Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002; 106(1):130-5. DOI: 10.1161/01.cir.0000020689.12472.e0. View

16.

Roberts A, Piek E, Bottinger E, Ashcroft G, Mitchell J, Flanders K . Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?. Chest. 2001; 120(1 Suppl):43S-47S. DOI: 10.1378/chest.120.1_suppl.s43-a. View

17.

Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y . Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996; 49(4):1120-6. DOI: 10.1038/ki.1996.162. View

18.

Yamamoto T, Nakamura T, Noble N, Ruoslahti E, Border W . Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993; 90(5):1814-8. PMC: 45970. DOI: 10.1073/pnas.90.5.1814. View

19.

Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T . Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361(9352):117-24. DOI: 10.1016/S0140-6736(03)12229-5. View

20.

Sharma K, Ziyadeh F . Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol. 1994; 267(6 Pt 2):F1094-01. DOI: 10.1152/ajprenal.1994.267.6.F1094. View